Analysis of the TROPION-Breast01 study showed that treatment with Dato-DXd did not significantly improve overall survival compared with chemotherapy in HR-positive, HER2-low or -negative breast cancer ...
Prithviraj Bose, MD, provides an overview of the different JAK inhibitors currently available for patients with myeloproliferative neoplasms. Prithviraj Bose, MD, professor in the Department of ...
Sun Gwe Ahn, MD, discusses an exploratory analysis of the HERA trial at the 2024 ESMO Congress. An exploratory analysis of the HERceptin Adjuvant (HERA; NCT00045032) trial investigated the benefits of ...